Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase I trial evaluates iPSC-derived CAR T-cell therapy FT-819 for CD19+ malignancies

Aug. 3, 2021

ST-067 enters first-in-human study in relapsed or refractory solid tumors

Aug. 3, 2021

Intranasal vaccination with ChAdOx1 nCoV-19 reduces viral shedding in preclinical models

Aug. 3, 2021

Abcentra studies orticumab in subjects with psoriasis and cardiometabolic risk factors

Aug. 3, 2021

Collagenase clostridium histolyticum improves foot function in plantar fibromatosis study

Aug. 3, 2021

China's NMPA approves INDs for IASO's CD19/CD22 CAR-T therapy

Aug. 3, 2021

Gem gene sparkles as ischemic stroke drug discovery target

Aug. 3, 2021

Phase II data show safety and efficacy of OCS-02 in dry eye disease

Aug. 3, 2021

Discovery of SR-42667: a tau-SH3 interaction inhibitor that prevents Abeta toxicity

Aug. 3, 2021

Prometheus initiates phase IIa APOLLO-CD study of PRA-023 in Crohn's disease

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...